Cocrystal Pharma Inc (COCP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $18.88M
Last updated: Nov 17, 2026 at 4:10 PM ET
Cocrystal Pharma Inc (COCP) Stock Chart
Cocrystal Pharma (COCP) has a latest price of $1.01 on Nov 17, 2026, 50.2% below its 52-week high of $2.03. Its price fell 1.9% over the past 12 months. The month-end price fell 99.4% over the 10 years through Oct 2026, a compound annual decline of 40.3%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $173.04 in Oct 2016 and its lowest $0.82 in Jul 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart COCP with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for COCP.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 11.8%, and over 6 months it fell 12.2%. The month-end price fell 41.8% over the 3 years through Oct 2026, a compound annual decline of 16.5%.
| Period | Change |
|---|---|
| 1 month | +6.7% |
| 3 months | -11.8% |
| 6 months | -12.2% |
| 12 months | -1.9% |
| 12 months, with dividends | -1.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -41.8% | -16.5% |
| 5 years | -90.7% | -37.8% |
| 10 years | -99.4% | -40.3% |
Price by Year
Its best calendar year was 2020, when the price rose 172.0%, and its weakest was 2019, when it fell 86.1%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $0.99 | +1.6% |
| 2025 | $0.98 | -51.5% |
| 2024 | $2.02 | +17.3% |
| 2023 | $1.72 | -11.7% |
| 2022 | $1.95 | -75.0% |
| 2021 | $7.80 | -52.2% |
| 2020 | $16.33 | +172.0% |
| 2019 | $6.00 | -86.1% |
| 2018 | $43.22 | -40.1% |
| 2017 | $72.10 | -48.1% |
Trading Range
The price is 6.0% below its 50-day average of $1.07 and 8.3% below its 200-day average of $1.10.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.01 | |
| 52-week high | $2.03 | -50.2% |
| 52-week low | $0.76 | +32.9% |
| 50-day average | $1.07 | -6.0% |
| 200-day average | $1.10 | -8.3% |
Price Risk
Over 3 years, its largest fall from a peak was 74.8%.
| Measure | Value |
|---|---|
| 1-year beta | 1.25 |
| Largest fall, 1 year | -47.8% |
| Largest fall, 3 years | -74.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About COCP
What is COCP's 1-year price change?
Cocrystal Pharma's price fell 1.9% over the past 12 months. With dividends included, the 12-month total return was -1.9%.
What is COCP's 5-year price change?
Cocrystal Pharma's month-end price fell 90.7% over the 5 years through Oct 2026, a compound annual decline of 37.8%. These figures leave out dividends.
What is COCP's 52-week high and low?
Cocrystal Pharma's 52-week high is $2.03 and its 52-week low is $0.76. Its latest price of $1.01 on Nov 17, 2026 is 50.2% below the high.
What is COCP's beta?
Cocrystal Pharma's 1-year beta against the S&P 500 is 1.25, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 47.8%.
Is the COCP chart free?
Yes. Advanced Charting for COCP is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
COCP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts